← All trials
NCT00545792
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2007
- Primary completion
- Nov 1, 2010
- Completion date
- Oct 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 21
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Harvard UniversityLead sponsor
- GenentechCollaborator
- Harvard UniversityOverall official - principal investigator
- Lowell General HospitalCollaborator
- Saint Anne's HospitalCollaborator
- Harvard UniversityReponsible party - principal investigator
- Harvard UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.